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TO THE EDITOR: A 63-year-old woman
presented with polyuria, polydipsia, leth-
argy and vomiting. Two weeks previously,
she had been diagnosed as having diffuse
scleroderma with possible interstitial lung
disease, and had started taking 50 mg
prednisolone daily. Her past history
included diabetes, hypertension, hypercho-
lesterolaemia and β-thalassemia trait, and
her other medications were metformin,
glibenclamide, quinapril and amlodipine.
Examination revealed blood pressure
150/60 mmHg, a loud second heart sound
with no murmurs, and late inspiratory
crepitations at lung bases. Her serum
creatinine concentration was 270 mol/L
(compared with 100 mol/L two weeks
previously) and serum glucose concentra-
tion was 26.5 mmol/L. Treatment by the
admitting doctor included insulin, rehydra-
tion, and cessation of prednisolone (given
hyperglycaemia) and quinapril (secondary
to acute renal impairment). She developed
a fever and cough, with bilateral pneumo-
nia, which was treated with intravenous
ceftriaxone.
Despite normotension, concern regard-
ing scleroderma renal crisis (SRC) was
raised. On Day 12 of admission, when renal
failure had developed to the dialysis-
dependent level (serum creatinine level,
690 mol/L), quinapril was recommenced
for its proposed renoprotective effect and
haemodialysis was initiated. Microangio-
pathic haemolytic anaemia (haemoglobin,
7.2 g/L) was diagnosed, with fragmented
red blood cells (Box).
Several months later, she continues on
haemodialysis three times a week. Renal
biopsy was not performed given the clinical
picture of diffuse scleroderma and recent
corticosteroid use with rapid development
of renal failure — consistent with SRC.
SRC is defined as rapidly progressive
renal failure and/or new onset of malignant
hypertension during the course of sclero-
derma, occurring in 15%–20% of patients
with the diffuse variety.1 Risk factors
include male sex, black race, and early
diffuse scleroderma with rapidly progressive
skin thickening.2 Precipitation of SRC by
corticosteroid use, especially in normoten-
sive patients, is well described, particularly
with high-dose (>15 mg/day) treatment.2
Early diagnosis is critical because treat-
ment may preserve renal function.3 Out-
comes have improved with use of
angiotensin-converting enzyme (ACE)
inhibitors,2 which are thought to improve
renal function by controlling the high renin
levels seen in patients with SRC. About
61% of patients have a good outcome, with
no or temporary dialysis.3 Predictors of
poor outcome, despite ACE inhibitor use,
include older age, male sex, higher initial
serum creatinine level, and scleroderma
myocardial disease.1 Eleven per cent of
SRC patients remain normotensive and
have significantly reduced 12-month sur-
vival rates.4 This may relate to delay in
diagnosis of SRC.
The use of high dose corticosteroids in
patients with early diffuse scleroderma
should be strongly discouraged, and inten-
sive monitoring for SRC is recommended if
low dose corticosteroids are required.
1. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North
Am 1996; 22: 861-878.
2. Steen VD, Medsger TA Jr. Case–control study of
corticosteroids and other drugs that either precipitate or
protect from the development of scleroderma renal crisis.
Arthritis Rheum 1998; 41: 1613-1619.
3. Steen VD, Medsger TA Jr. Long-term outcomes of sclero-
derma renal crisis. Ann Intern Med 2000; 133: 600-603.
4. Helfrich DJ, Banner B, Steen VD, Medsger TA Jr.
Normotensive renal failure in systemic sclerosis. Arthritis
Rheum 1989; 32: 1128-1134. ❏
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TO THE EDITOR: Comprehensive care has
been shown to improve outcome in asthma
management when it has four components
— asthma education, self-monitoring, writ-
ten self-management plans, and regular
medical review.1,2
A recent Cochrane Review has explored
the role of one of these components —
written self-management plans — and
concluded that there is “no consistent
evidence that written plans produced better
patient outcomes”.3 Should this cause us to
change our management strategies in
Australian general practice? Does this mean
that our patients are not able to care for
their own asthma without our intensive
assistance?
These findings update a 1998 review of
the role of written asthma management
plans as part of comprehensive care in
1998: “In five studies which compared
subjects who managed their asthma by self-
adjustment according to individualised
written plan with those whose medications
were adjusted by the doctor, lung function
data (FEV1 [forced expiratory volume in
one second] and PEF [peak expiratory
flow]) were significantly higher in the self-
managed group.”1
In Australian general practice, between
30% and 50% of patients are given a written
asthma management plan.4 These plans
form part of known beneficial comprehen-
sive asthma care plans, such as the Six-Step
Asthma Management Plan5 or the Asthma
3+ Visit Plan.4
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The small number of available high
quality trials for this most recent review led
the authors to say, “Available trials are too
small and the results too inconsistent to
form any firm conclusions”, and suggests
that more trials are needed to produce a
conclusive result.3
We should be careful not to lose the
positive effects of improved chronic disease
management in asthma by over-responding
to this one review of one component of
comprehensive care.
1. Gibson PG, Coughlan J, Wilson AJ, et al. The effects of
self-management education and regular practitioner
review in adults with asthma. The Cochrane Library, Issue
4, 1998. Oxford, Update Software.
2. Gibson PG, Coughlan J, Wilson AJ, et al. Self-
management education and regular practitioner review for
adults with asthma. The Cochrane Library, Issue 3, 2001.
Oxford: Update Software.
3. Toelle BG, Ram FSF. Written individualised management
plans for asthma in children and adults (Cochrane
Review). The Cochrane Library, 2002. Issue 3. Oxford:
Update Software.
4. Bubner T, Duszynski A, Beilby J. Final report: asthma 3+
visit plan executive summary and recommendations.
Adelaide: Adelaide University: Department of General
Practice, 2002.
5. Coughlan J, Wilson A, Gibson P. Summary report of the
1999 evidence-based review of the Australian six step
asthma management plan. Sydney: NSW Health, 2000. ❏
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COMMENT: A Cochrane systematic review
identified the beneficial effects of planned
asthma management and education that
includes a written action plan.1 These
findings have now been adapted for primary
care and implemented as the Asthma 3+
Visit Plan. This involves a systematic
assessment of asthma symptoms, lung
function, and current treatment at each
visit. Treatment and management skills are
optimised and the patient is given written
instructions on how and when to increase
treatment when asthma deteriorates (a
written action plan).
A recent Cochrane review asked whether
one can get the same benefits by doing less
— by simply supplying a patient with a
written action plan.2 The review found that
the literature was inconclusive. This doesn’t
mean that written action plans are not
effective; it means that there is not enough
evidence to be able to answer the question.
The result of “no evidence of effect” is
completely different to “evidence of no
effect”.3,4 This is a crucial distinction, as
many systematic reviews find insufficient
evidence to be able to assess a treatment.
This is a statement about our ignorance
rather than a statement about whether a
treatment works or not.
The review also highlights the need to
carefully evaluate the control intervention.
For example, the control groups in two
studies in the systematic review2 received
regular medical review, with assessment of
severity and optimisation of inhaled steroid
therapy. It is not surprising that these
studies found it difficult to identify any
additional effect of an action plan.
Cochrane systematic reviews conclude
with recommendations for clinical practice
that highlight effective treatments,1 and
with recommendations for research that
indicate where more information is
needed.2 The review looking at just supply-
ing patients with written action plans2
exemplifies the latter.
1. Gibson PG, Coughlan J, Wilson AJ, et al. The effects of
self-management education and regular practitioner
review in adults with asthma. The Cochrane Library, Issue
4, 1998. Oxford, Update Software.
2. Toelle BG, Ram FSF. Written individualised management
plans for asthma in children and adults. The Cochrane
Library, Issue 3, 2002. Oxford, Update Software.
3. Rothwell PM. Why do clinicians sometimes find it difficult to
use the results of systematic reviews in routine clinical
practice? Eval Health Prof 2002; 25: 200-209.
4. Ezzo J, Bausell B, Moerman DE, et al. Reviewing the
reviews. How strong is the evidence? How clear are the
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TO THE EDITOR: I read with great interest
the article by Byard et al,1 as well as the
previous work by these authors on parame-
thoxyamphetamine (PMA)-related fatalities
in South Australia.2 In 2001, I encountered
a similar fatal “outbreak” in Belgium: six
fatal cases, four of them in the Antwerp
metropolitan area.3,4 Striking similarities
between the Belgian and Australian fatali-
ties include the clinical symptoms, the
autopsy findings and the history of alleged
“ecstasy” intake. Pure PMA tablets were
found on a victim with an “xTc” logo
pressed onto the surface of the tablets.3
I agree with Byard et al1 that the sudden
“outbreaks” of death from PMA intoxication
probably do not result from contamination
during the synthesis of 3,4-methylene-
dioxymethamphetamine (MDMA). In Bel-
gium, there are strong indications that the
resurgence of PMA resulted from a legal
loophole. Early in 2001, PMA was encoun-
tered for the first time in the blood sample of
a young girl who presented to an emergency
department for alleged ecstasy intoxication.
A few weeks later, the first fatal case was
reported, and over a period of a few months
five other fatal cases were seen.
After the first two deaths, PMA captured
a lot of media attention and even evoked
some political disturbance. By the end of
2001, PMA and its precursor molecule, p-
methoxyphenylacetone, were placed on the
list of regulated and restricted substances
(and hence the unauthorised possession of
these products became a criminal offence).
Afterwards, no more fatalities were
reported. I therefore hypothesise that illicit
amphetamine manufacturers were aware of
the (temporary) legal vacuum in Belgian
law before the deaths occurred and substi-
tuted PMA for MDMA because PMA
precursors were easier to obtain and less
strictly controlled by legislation. It has been
suggested in the Australian illicit drug report
1994,5 as well as by Byard et al,3 that
manufacturers of PMA may have been
deliberately marketing it as another drug
(eg, MDMA) or may have promoted it
specifically as a drug to augment the effects
of MDMA. If this is the case, there may be
serious implications for criminal liability, as
we now know that PMA intoxication has a
significantly worse clinical outcome than
MDMA intoxication (including a greater
likelihood of QRS-interval prolongation,
extreme hyperthermia, seizures and a
significantly lower score on the Glasgow
Coma Scale).6
1. Byard RW, Rodgers NG, James RA, et al. Death and
paramethoxyamphetamine — an evolving problem. Med J
Aust 2002; 176: 496.
2. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine
derivative fatalities in South Australia — is “ecstasy” the
culprit? Am J Forensic Med Pathol 1998; 19: 261-265.
3. Voorspoels S, Coucke V, Schepens P, Jacobs W.
Paramethoxyamphetamine: first fatalities in Belgium. Bull
TIAFT 2001; 31: 12-13.
4. Voorspoels S, Coucke V, Covaci A, et al. Resurgence of a
lethal drug: paramethoxyamphetamine deaths in Belgium.
J Toxicol Clin Toxicol 2002; 40: 203-204.
5. Australian illicit drug report 1994. Canberra: Australian
Bureau of Criminal Intelligence, 1995.
6. Ling LH, Marchant C, Buckley NA, et al. Poisoning with the
recreational drug paramethoxyamphetamine (“death”).
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TO THE EDITOR: I read with interest the
MJA supplement The student and junior
doctor in distress — “our duty of care”.1 It is
encouraging to see the time, effort and
research currently being devoted to the
health and mental wellbeing of our col-
leagues.
